Stocks to Buy based on the Best Stock Market Research
Histogenics (HSGX) stock is rallying 53% to $2.35 in pre market after the company released positive NeoCart Phase 1 and 2 data.
Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
– Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months –
– Improvements in cartilage quality were accompanied by consistent and statistically significant improvements in patient reported clinical outcomes as early as 3 to 6 months after implantation –
– Data underscore potential to provide a faster and more durable recovery for patients with cartilage defects in the knee –
More Stocks to Watch - http://www.blackberrystocks.com/stockstowatch.html